🔎 Trials Near Me

Home › Bipolar Disorder › NCT06372964

Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients

RecruitingPhase 3

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Lumateperone for the Treatment of Major Depressive Episodes (MDEs) Associated With Bipolar I or Bipolar II Disorder (Bipolar Depression) in Pediatric Patients Aged 10 to 17 Years

Who can join

Ages 10 to 17 · All sexes

Full eligibility criteria
Inclusion Criteria:

1. Able to provide consent as follows:

   * The Legally Authorized Representative (LAR) must provide written, informed consent.
   * The patient must provide written assent;
2. Male or female patients 10 to 17 years of age, inclusive;
3. Have a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision (DSM-5-TR) primary diagnosis of bipolar I or bipolar II disorder with a current MDE without psychosis as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL);
4. Subject has a lifetime history of at least one manic or hypomanic episode.
5. Subject's current major depressive episode is ≥ 4 weeks and less than 12 months in duration;
6. CDRS-R total score ≥ 45 with ≥ 5 on Item 11 (depressed feelings) at Screening and Baseline;
7. Young Mania Rating Scale (YMRS) score ≤ 15 (with YMRS Item 1 \[elevated mood\] score ≤ 2) at Screening and Baseline.

Exclusion Criteria:

1. Has a primary psychiatric diagnosis other than bipolar I or bipolar II disorder. Exception includes:

   * Attention deficit hyperactivity disorder (ADHD). If a subject is taking medications for ADHD, they must have been on a stable treatment regimen of these medication(s) for 30 days prior to screening and the treatment regimen is expected to remain stable throughout the study.
2. Intellectual disability based on Investigator opinion and DSM-5 criteria
3. Patient has been hospitalized for a bipolar manic episode within the 30 days prior to randomization;
4. Demonstrates a ≥ 25% decrease (improvement) in the CDRS-R total score between Screening and Baseline visits, or the CDRS-R is below 45 at Baseline;
5. In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during his/her participation in the study or

   1. At Screening, the patient scores "yes" on Suicidal Ideation Items 3, 4, or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) within 6 months prior to Screening or, at Baseline, the patient scores "yes" on Suicidal Ideation Items 3, 4, or 5 since the Screening Visit;
   2. At Screening, the patient has had 1 or more suicidal attempts within the 2 years prior to Screening; or
   3. At Screening or Baseline, scores \> 3 on Item 13 (suicidal ideation) on the CDRS-R; or
   4. The patient is considered to be an imminent danger to him/herself or others.

About the study

This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs) associated with a primary diagnosis of bipolar I or bipolar II disorder as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL), according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).

What is being tested

Sponsor: Intra-Cellular Therapies, Inc. · Participants: 384 · Started: May 14, 2024

Contact the study team

Official record on ClinicalTrials.gov — NCT06372964

Locations in the U.S.

AlabamaHarmonex Neuroscience Research, Dothan
ArkansasPillar Clinical Research, LLC, Little Rock
CaliforniaAdvanced Research Center, Inc, Anaheim
Inland Psychiatric Medical Group Inc, Redlands
UC Davis Health System, Sacramento
Next Level Clinical Trials, LLC, West Covina
FloridaCare Research Center Inc, Miami
Envision Trials LLC, Miami
HealthMed Clinical Center Inc, Miami
Links Clinical Trials, Miami
New Med Research Inc, Miami Gardens
The Angel Medical Research Corporation, Miami Gardens
Riveldi Biomedical Research, Miami Lakes
APG Research LLC, Orlando
Health Synergy Clinical Research, West Palm Beach
GeorgiaCenExeli Research LLC, Atlanta
CenExeli Research LLC 1, Savannah
IllinoisAnn & Robert H. Lurie Children's Hospital of Chicago, Chicago
Revive Research Institute, Elgin
MichiganNeurobehavioral Medicine Group, Bloomfield Hills
MissouriMidwest Research Group, Saint Charles
NebraskaAlivation Research LLC, Lincoln
New YorkNYU Child Study Center, New York
OhioUniversity of Cincinnati Medical Center, Cincinnati
Charak Center for Health and Wellness, Garfield Heights
OklahomaSP Research, PLLC (dba Rivus Wellness & Research Institute), Oklahoma City
Sooner Clinical Research, Oklahoma City
TexasThe University of Texas at Austin, Austin
REX Clinical Trials LLC, Beaumont
Kaleidoscope Clinical Research, Houston
Perceptive Pharma Research, Richmond
VirginiaVirginia Commonwealth University, Richmond
WashingtonNorthwest Clinical Research Center, Bellevue
Core Clinical Research, Everett

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.